Navigation Links
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
Date:4/23/2009

NEW HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin(TM) (laromustine) Injection has received a standard review classification by the U.S. Food and Drug Administration (FDA). Therefore, a user fee goal date of December 12, 2009 for a decision by the FDA with respect to the approval of the Company's NDA has been established.

The Company had previously announced the acceptance of the NDA filing for review by the FDA on April 16, 2009. The NDA presents data for Onrigin(TM) as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Our level of excitement continues to grow as we move forward in the FDA's process of reviewing our NDA. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin(TM) in its first indication in the United States." He added, "The positive news today is that we can expect to have an FDA decision this year."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM)(laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Applicat
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
5. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... brain development, the brains first cells neuroepithelial stem cells ... evolves into the various cells of the fully formed brain. ... critical for these stem cells to divide correctly. Without it, ... offers insight into the first steps of brain development, and ...
... QMed, Inc. (Nasdaq:,QMED) today announced financial results for ... Revenue for the year decreased to,$5,246,789 from $8,136,305 a ... $(0.66) per share on a diluted basis, compared to ... basis the previous year.,Revenue for the three-month period ended ...
... hairdressers, barbers , , WEDNESDAY, March 26 (HealthDay News) -- ... had high concentrations of coloring ingredients appear to be ... new report contends. , The authors said the findings ... -- that hair dyes appear to increase the risk ...
... Emergency Medicine is hosting the 11th annual Society of ... Mesa, Calif. As part of the forum, UC Irvine ... variety of related areas ranging from the continued decline ... computerized alcohol-use counseling. , Emergency department ...
... Aging Specialist to Consult with Award-Winning Mind Fitness ... America Conference,Booth #1317) -- CogniFit, Ltd., the company ... software that will enhance human cognitive,performance and health, ... of,Gloria Cavanaugh, long-time president of the American Society ...
... protein, study says. , , WEDNESDAY, March 26 (HealthDay News) -- Keeping ... because it,s harder for women to replace muscle that,s lost naturally ... of 29 healthy women and men, aged 65 to 80, found ... mass -- a key difference in the way women,s and men,s ...
Cached Medicine News:Health News:Key factor in brain development revealed, offers insight into disorder 2Health News:Key factor in brain development revealed, offers insight into disorder 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 2Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 3Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 4Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 5Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 6Health News:QMed, Inc. Reports Year-End and Fourth Quarter Results 7Health News:Now-Banned Hair Dyes Linked to Bladder Cancer 2Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Older Women Have Harder Time Preserving Muscle Than Men 2
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... Market - Global Industry Analysis, Size, Share, Growth, ... to their offering. (Logo: ... are products which are used on patients in ... and in treatment of associated gingival tissues. This ...
(Date:1/15/2014)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ... from institutional investors to purchase an aggregate of ... in an at-the-market registered direct offering, led by ... Company entered into definitive purchase agreements with these ... sell an aggregate of 3,603,603 shares of its ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ... with Teva Pharmaceutical Industries Ltd (NYSE: TEVA ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Endologix, Inc. (Nasdaq: ELGX ), developer and ... today that the first U.S. commercial implant of the ... Hines, Jr. VA Hospital in Chicago, IL. The procedure ... and Chief of Vascular Surgery & Endovascular Therapy at ...
... Britain,s best-loved comedienne and TV favourite Jo Brand has joined ... for a brand new comedy film (54 seconds) to launch ... film sees Jo Brand running around South London, in what ... her kitchen with Joanna Scanlan and produces a pint of ...
Cached Medicine Technology:Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 2TV Favourite Jo Brand Puts Her Best Foot Forward for Macmillan Cancer Support 3
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: